Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy

Netherlands Journal of Medicine

Volumn 68, Issue 7-8, 2010, Pages 299-303

  Kusters, D M ^a,b   Homsma, S J M ^a   Hutten, B A ^c   Twickler, M T B ^a   Avis, H J ^a,b   van der Post, J A ^d   Stroes, E S G ^a  

^a Departments of Vascular Medicine   (Netherlands)

^b Departments of Paediatrics   (Netherlands)

^c Departments of Clinical Epidemiology   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Familial hypercholesterolaemia; Pregnancy; Statins; Teratogenicity

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FETUS DEVELOPMENT; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MOTHER CHILD RELATION; NONHUMAN; PREGNANCY; REVIEW; TERATOGENICITY;

ADULT; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; EVIDENCE-BASED MEDICINE; FEMALE; FETAL DISEASES; FETUS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MATERNAL WELFARE; NETHERLANDS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE; RISK ASSESSMENT; TERATOGENS;

EID: 77957744393     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Valle D, Sly WS, editors. The metabolic & molecular bases of inherited disease. 8 ed. 2001, pp. 2863-2913.
2. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1-14.
3. Walma EP, Visseren FL, Jukema JW, Kastelein JJ, Hoes AW, Stalenhoef AF. [The practice guideline 'Diagnosis and treatment of familial hypercholesterolaemia' of the Dutch Health Care Insurance Board]. Ned Tijdschr Geneeskd. 2006;150(1):18-123.
4. Thorogood M, Seed M, De Mott K. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG. 2009;116(4):478-479.
5. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 2004;109(23Suppl 1):III33-III38.
6. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med. 2004;350(15):1579-1582.
7. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol. 1996;10(6):439-446.
8. Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol. 2005;73(11):888-896.
9. Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA. Maternal exposure to statins and risk for birth defects: a case-series approach. Am J Med Genet A. 2008;146A(20):2701-5.
10. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007;64(4):496-509.
11. Taguchi N, Rubin ET, Hosokawa A, Choi J, Ying AY, Moretti ME, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26(2):175-177.
12. Avis HJ, Hutten BA, Twickler MT, Kastelein JJ, van der Post JA, Stalenhoef AF, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? Curr Opin Lipidol. 2009;20(6):484-490.
13. Martin U, Davies C, Hayavi S, Hartland A, Dunne F. Is normal pregnancy atherogenic? Clin Sci. (Lond) 1999;96(4):421-425.
14. Berge LN, Arnesen E, Forsdahl A. Pregnancy related changes in some cardiovascular risk factors. Acta Obstet Gynecol Scand. 1996;75(5):439-442.
15. Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, et al. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis. 2006;189(2):451-457.
16. Saarelainen H, Laitinen T, Raitakari OT, Juonala M, Heiskanen N, Lyyra-Laitinen T, et al. Pregnancy-related hyperlipidemia and endothelial function in healthy women. Circ J. 2006;70(6):768-772.
17. Ness RB, Harris T, Cobb J, Flegal KM, Kelsey JL, Balanger A, et al. Number of pregnancies and the subsequent risk of cardiovascular disease. N Engl J Med. 1993;328(21):1528-1533.
18. Kharazmi E, Moilanen L, Fallah M, Kaaja R, Kattainen A, Kahonen M, et al. Reproductive history and carotid intima-media thickness. Acta Obstet Gynecol Scand. 2007;86(8):995-1002.
19. Roes EM, Sieben R, Raijmakers MT, Peters WH, Steegers EA. Severe preeclampsia is associated with a positive family history of hypertension and hypercholesterolemia. Hypertens Pregnancy. 2005;24(3):259-271.
20. Redecha P, van Rooijen N, Torry D, Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood. 2009;113(17):4101-4109.
21. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 1999;354(9186):1234-1241.
22. Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100(11):2680-2690.
23. Napoli C, de Nigris F, Welch JS, Calara FB, Stuart RO, Glass CK, et al. Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. Circulation. 2002;105(11):1360-1367.
24. Palinski W, D'Armiento FP, Witztum JL, de Nigris F, Casanada F, Condorelli M, et al. Maternal hypercholesterolemia and treatment during pregnancy influence the long-term progression of atherosclerosis in offspring of rabbits. Circ Res. 2001;89(11):991-996.
25. Elahi MM, Cagampang FR, Anthony FW, Curzen N, Ohri SK, Hanson MA. Statin treatment in hypercholesterolemic pregnant mice reduces cardiovascular risk factors in their offspring. Hypertension. 2008;51(4):939-944.
26. Palinski W, Napoli C. The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J. 2002;16(11):1348-1360.
27. Alkemade FE, Gittenberger-de Groot AC, Schiel AE, Van Munsteren JC, Hogers B, van Vliet LS, et al. Intrauterine exposure to maternal atherosclerotic risk factors increases the susceptibility to atherosclerosis in adult life. Arterioscler Thromb Vasc Biol. 2007;27(10):2228-2235.
28. Napoli C, Witztum JL, Calara F, de Nigris F, Palinski W. Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses. Circ Res. 2000;87(10):946-952.
29. Corsini A, Windler E, Farnier M. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil. 2009;16(1):1-9.